Peter Ch’en Receives Travel Fellowship Award from SID

Congratulations to Peter Ch’en, a Clinical Research Fellow in the Merkel Cell Carcinoma Collaborative (MC3) Institute, on receiving a Travel Fellowship Award from the Society for Investigative Dermatology (SID)! 

This award will support Peter’s travel to the 2025 SID Annual Meeting, taking place in San Diego from May 7–10, where he will present his clinical research on the outcomes of patients that have immunotherapy-refractory Merkel cell carcinoma (MCC).

His session titled, “Real-world outcomes of patients receiving salvage therapies for immune checkpoint-resistant Merkel cell carcinoma: A rationale for future clinical trials,” highlights important findings that contribute to the evolving landscape of treatment for this challenging disease, and the need for new therapies. 

"I am honored to receive this award from the SID to present our team’s work. While the introduction of immune checkpoint inhibitors (ICI) has made significant strides in improving survival outcomes for advanced MCC, the 60% of patients who ultimately experience disease progression on ICI have limited systemic therapy options. This study clearly highlights the need to develop novel targeted therapies for this population and establishes benchmark survival metrics for new treatments to surpass." —Peter Ch'en

Congratulations on this well-earned recognition, Peter! Wishing you safe travels and success as you share this impactful work. 

SID Session Information 

Title: "Real world outcomes of patients receiving salvage therapies for immune checkpoint-resistant Merkel cell carcinoma: A baseline for future clinical trials" 
Author: Peter Ch'en (Nghiem Lab/MC3 Institute)  
Category: Clinical Research: Epidemiology and Observational Research 
Time/Location: 8:30-11:15 a.m. (CM8-06) | Sapphire A/B 
Session: Concurrent Mini-symposium 8: Clinical Research - Epidemiology and Observational Research II